Highlights

  • Citius Oncology reported a quarterly loss of USD 0.06 per share during the period.
  • Shares traded about 1.6% higher intraday, reaching USD 1.27 on Tuesday.
  • Institutional investors held more than 70% of outstanding shares during the quarter.

Citius Oncology, Inc. (NASDAQ:CTOR) released its quarterly earnings results on December 23, reporting a loss for the period. The company posted earnings per share (EPS) of negative USD 0.06, according to data referenced by Zacks Investment Research. The results reflected continued losses during the quarter, consistent with the company’s financial profile as a clinical-stage oncology firm.

Financial Position
Citius Oncology reported a current ratio of 0.35 and a quick ratio of 0.02, reflecting limited short-term liquidity. The company’s debt-to-equity ratio stood at 0.12, indicating relatively low leverage compared with equity. These figures highlight the company’s balance sheet position during the reported quarter.

Institutional Ownership
Institutional investors accounted for approximately 70.52% of Citius Oncology’s outstanding shares. During recent quarters, several firms adjusted their holdings. Armistice Capital LLC reported a new position valued at about USD 15.58 million during the third quarter. Other institutional participants included Geode Capital Management LLC, Jane Street Group LLC, Citadel Advisors LLC, and Bank of America Corp DE, which significantly increased its stake from a low base.

Share Price Movement
Following the earnings release, shares of Citius Oncology traded higher during midday trading. The stock rose by approximately  1.6%, to USD 1.27. The stock’s 50-day moving average stood at USD 1.40, while the 200-day moving average was USD 1.90.

Over the past 52 weeks, shares have traded between a low of USD 0.55 and a high of USD 6.19. At the reported share price, the company carried a market capitalisation of approximately USD 106.06 million.